Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial

Abstract. Despite the availability of vasodilating compounds, pulmonary hypertension (PH) of various origins remains a disease with a poor prognosis. In recent years, pulmonary arterial hypertension (PAH) has been recognized as a predominantly proliferative process. Everolimus, an inhibitor of the m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Seyfarth, Hans-Jürgen, Hammerschmidt, Stefan, Halank, Michael, Neuhaus, Petra, Wirtz, Hubert R.
Format: Artigo
Jezik:Inglês
Izdano: University of Chicago Press 2013
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4070806/
https://ncbi.nlm.nih.gov/pubmed/24618547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/674311
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki